FDA Clearance Validates Platform Designed to Deliver Electronic X-ray-Based Therapy Directly to Cancer Sites in Minimally Shielded Clinical Settings
SUNNYVALE, Calif., March 17 /PRNewswire/ -- Xoft, Inc., today announced that it has received expanded clearance from the U.S. Food & Drug Administration (FDA) for the Axxent(R) Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings. Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System is now cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated.
As a platform technology, the Axxent Electronic Brachytherapy System is designed to address a variety of oncological and non-oncological indications. Xoft is actively working to extend the use of Electronic Brachytherapy to endometrial and rectal indications, which are pending FDA clearance.
"The prospect of expanding the use of Electronic Brachytherapy beyond our breast cancer patients is very exciting," said Adam Dickler, radiation oncologist at Little Company of Mary Hospital in Chicago. "The ability to deliver electronic X-ray based therapy directly to the cancer site spares healthy tissue and gives us the ability to provide that therapy in a broader spectrum of clinical settings. This tool has been very well received by our breast cancer patients and we would expect it deliver similar benefits across a range of cancer treatments."
Designed to deliver electronic, X-ray-based radiation treatment, the
proprietary Axxent treatment platform can be used in virtually any clinical
setting under the supervision of a radiation oncologist. The Axxent System
is designed to deliver non-radioactive therapy directly to cancer sites
with minimal radiation exposure to surrounding healthy tissue. Eliminating
the need for heavily shielded envir
|SOURCE Xoft, Inc.|
Copyright©2008 PR Newswire.
All rights reserved